- Home
- MCRI vs SDGR Comparison
MCRI vs SDGR Comparison
Compare MCRI & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- SDGR
- Stock Information
- Founded
- MCRI 1972
- SDGR 1990
- Country
- MCRI United States
- SDGR United States
- Employees
- MCRI N/A
- SDGR N/A
- Industry
- MCRI Hotels/Resorts
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- MCRI Consumer Discretionary
- SDGR Health Care
- Exchange
- MCRI Nasdaq
- SDGR Nasdaq
- Market Cap
- MCRI 1.5B
- SDGR 1.8B
- IPO Year
- MCRI 1993
- SDGR 2020
- Fundamental
- Price
- MCRI $75.63
- SDGR $25.75
- Analyst Decision
- MCRI Hold
- SDGR Buy
- Analyst Count
- MCRI 5
- SDGR 7
- Target Price
- MCRI $87.20
- SDGR $33.00
- AVG Volume (30 Days)
- MCRI 110.3K
- SDGR 1.5M
- Earning Date
- MCRI 04-22-2025
- SDGR 04-30-2025
- Dividend Yield
- MCRI 1.60%
- SDGR N/A
- EPS Growth
- MCRI N/A
- SDGR N/A
- EPS
- MCRI 3.84
- SDGR N/A
- Revenue
- MCRI $522,186,000.00
- SDGR $207,539,000.00
- Revenue This Year
- MCRI $3.88
- SDGR $24.12
- Revenue Next Year
- MCRI $2.76
- SDGR $18.60
- P/E Ratio
- MCRI $19.70
- SDGR N/A
- Revenue Growth
- MCRI 4.13
- SDGR N/A
- 52 Week Low
- MCRI $64.50
- SDGR $16.60
- 52 Week High
- MCRI $96.11
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- MCRI 41.75
- SDGR 64.18
- Support Level
- MCRI $69.99
- SDGR $23.57
- Resistance Level
- MCRI $76.34
- SDGR $26.86
- Average True Range (ATR)
- MCRI 3.35
- SDGR 2.12
- MACD
- MCRI 0.26
- SDGR 0.86
- Stochastic Oscillator
- MCRI 50.77
- SDGR 89.18
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.